everolimus

This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.

Afinitor and Uptravi gain funding from NHS England

Around 70 people in England are currently prescribed everolimus for TSC-related kidney and brain tumours. ... NHS England estimates that a further 300 people in England will benefit from treatment with everolimus for TSC-related refractory epilepsy.

Latest news

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been
AAA board presses go on $3.9bn Novartis takeover

Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective,
NICE U-turn on Novartis' Afinitor for kidney cancer

cancer. The U-turn on NICE's 2011 decision comes as the regulator continues its reappraisal of all therapies supported by the Cancer Drugs Fund (CDF), with Afinitor (everolimus) previously only
NICE backs Novartis' Afinitor and Pfizer's Xalkori

Afinitor (everolimus) has been backed as a combination treatment with Pfizer's Aromasin (exemestane) for the treatment of postmenopausal women with HER2-negative hormone-receptor-positive advanced breast cancer - the most ... organs. Prof Carole Longson,
NICE U-turn on Opdivo for kidney cancer

In a phase III clinical study, patients treated with Opdivo lived for an average of 5.4 months longer than the group who received Novartis' Afinitor (everolimus), the standard therapy, and

More from news
Approximately 8 fully matching, plus 62 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Healthcare Marketing Agency: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Medical Writer: Salary TBC

Account Director, Medical Education: Salary TBC

Global Business Development Director – Health Education: excellent commission

Account Director – Health Policy – Global Agency: Salary TBC

Associate Director: £75, 000-90, 000

Account Manager / Account Director: Competative

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Medical Writer: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...